You can support lung cancer research.
A clinical trial for people who have not yet been treated for advanced non-small cell lung cancer (NSCLC) is now enrolling. See if you qualify.
Learn about a clinical trial for previously treated non-small cell lung cancer (NSCLC)
The Be6A LUNG-02 Clinical Trial is evaluating the safety and effectiveness of a study medicine (sigvotatug vedotin) used with a standard therapy (pembrolizumab) in people who have not yet been treated for advanced non-small cell lung cancer (NSCLC).
Who may participate
Deciding to take part in a clinical trial is an important and personal decision. Before you agree to take part, the study team will review all aspects of the clinical trial with you. You will be given a document called an Informed Consent Document (ICD) that provides, in writing, details about the clinical trial including benefits and risks. You will have the opportunity to ask questions and are encouraged to speak to your own doctor to decide if taking part is right for you.
You may be eligible to take part in the clinical trial if you:
- are at least 18 years of age (or the legal age of consent where the clinical trial is taking place)
- have been diagnosed with Stage III or Stage IV (metastatic) non-small cell lung cancer
- have not yet been treated for your advanced lung cancer
- have high PD-L1 (the study team can confirm if you are not sure)
This is not a complete list of the eligibility criteria for this clinical trial. The study doctor will review all the criteria with you.
Condition
Advanced non-small cell lung cancer (NSCLC)
Age
Over 18 years of age
Sex
Male or Female
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enrol in the study.
What to expect
In the clinical trial, the combination therapy (the study medicine + the standard therapy) will be compared to using the standard therapy alone. You will have a 1 in 2 (50%) chance of receiving the combination therapy or the standard therapy alone.
Additionally, you will get the following at no extra cost:
- the standard therapy; some participants may also receive the study medicine
- all study-related medical examinations
- close monitoring of your cancer and overall health by doctors who specialise in lung cancer
- reimbursement (you may be paid back) for some of the qualified travel and lodging costs for you and your carer, if applicable.
Your participation may help increase medical knowledge about non-small cell lung cancer for the future.
Length of study duration
Up to 5 years
Number of study visits
5 visits in the first cycle, and up to 3 visits for all other cycles
Long-term follow-up
Every 6 weeks for the first year and every 3 months afterwards
Why are we conducting the Be6A LUNG-02 Study?
The main goals of this clinical trial are to understand:
- whether life expectancy is extended
- the percentage of patients who respond to the study medicine when used with the standard therapy
- whether there is an increase in the time that the cancer doesn’t spread
- whether there are changes to/improvements in quality of life
This is not a complete list of the clinical trial’s goals. The study doctor can review the complete list with you.
Your safety while participating is our highest priority. If you have questions or concerns at any point throughout the clinical trial, a study team member is available to talk to you. Your privacy will be maintained throughout the clinical trial. Your participation is voluntary, and you are free to withdraw from the clinical trial at any time. Your study doctor may end your participation if they feel the clinical trial is not in your best interest.
About the study medicine
The study medicine is designed to stick to cancer cells and kill them by delivering an anticancer treatment. The study medicine may also attach to non-cancer cells.
The study medicine is given by intravenous (through a vein) infusion in a cycle that repeats every 6 weeks. Infusions of the study medicine are given 3 times per cycle (Day 1, Week 2, and Week 4). The standard therapy is given by intravenous infusion 1 time (Day 1) during every 6-week cycle.
Clinical trial locations
Enter your post code to see the nearest trial site locations.
Frequently asked questions
About the Be6A LUNG-02 clinical trial
Deciding to take part in a clinical trial is an important and personal decision. Before you agree to take part, the study team will review all aspects of the clinical trial with you. You will be given a document called an Informed Consent Document (ICD) that provides in writing the clinical trial’s purpose, assessments, procedures, benefits, risks and precautions. You will have the opportunity to ask questions and are encouraged to speak to your own doctor to decide if taking part is right for you.
All study-related medical care and the standard therapy and/or the study medicine will be provided at no extra cost. You and your carer may also be paid back for some qualified travel and accomodation costs, if applicable.
No, there is no placebo in this clinical trial. All participants will receive the standard therapy (pembrolizumab). Some participants will also get the study medicine (sigvotatug vedotin).
A study medicine is a medicine that has not been approved by regulatory or health authorities (e.g. the European Medicines Agency [EMA] or appropriate regulatory authorities in each country) for prescription use.
The study medicine is designed to stick to cancer cells and kill them by delivering an anticancer treatment. The study medicine may also attach to non-cancer cells.
Yes, the information you provide will not be shared with anyone who is not directly associated with this clinical trial without your permission, except as required by law or as set forth in the informed consent.
No, your doctor does not have to give you permission to take part. However, feel free to talk to your doctor about participating. With your permission, the study doctor will keep your regular doctor updated about your condition during the clinical trial.
Yes, taking part in any clinical trial is completely voluntary. If you decide to take part, you are free to withdraw at any time, for any reason and without any penalty or effect on your future medical care. If you are in the clinical trial and decide to leave it, you should talk to your study doctor about leaving so that they can end your participation in the safest way.
About clinical trials
Clinical trials (or research studies) are a type of medical research in which people volunteer to take part. Clinical trials commonly study how potential medicines and other medical treatments affect the participants.
All medicines and vaccines that become available today for use in patients are first tested in clinical trials involving hundreds to thousands of people.
As part of a clinical trial, your study-related medical care is provided by the study team at the location where you are participating in the trial. This includes the principal investigator (or study doctor) — the healthcare professional who conducts and takes responsibility for the trial at that location — as well as other clinical study team members. To help make sure that a clinical trial is ethical, and that participants’ rights are protected, Institutional Review Boards (IRBs) or Ethics Committees (ECs) review study protocols.
We encourage everybody to consider joining clinical trials. There are many types of clinical trials that study different aspects of health in people with a variety of backgrounds and conditions. Each clinical trial has its own criteria for who may participate. These are called eligibility criteria.
Eligibility criteria include things like your age, sex, overall health, type of condition and your medical treatment history. As part of the steps to join a clinical trial, the study doctor will confirm whether you meet all eligibility criteria and are able to participate.
Participation in a clinical trial is always voluntary. The decision to join is personal, and it is fully yours.